We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 296.00 | 293.00 | 296.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/7/2018 07:56 | miti, no, planning to do that today To my mind, whatever contract Chi-Med had with AZ will still be valid and transfer across to Luye as part of the deal | nerdofsteel | |
02/7/2018 06:52 | Nerdofsteel, have you emailed him about Seroquel ? Its an important question. | miti 1000 | |
29/6/2018 15:34 | Just came across this post from Oct 2011 on iii:- Great little company with an excellent future but short term unfortunately It's Chinese It's on AIM It's jam tomorrow , low revenues loss making support on chart looks questionable at £2.50 and £2. this dropped to sub 50p in the 08/09 trauma John09 certainly mis-read what this Co is all about | nerdofsteel | |
29/6/2018 10:17 | Interesting article in today's Times regarding Seroquel. AZ sold rights of Seroquel to Luye Pharma, a HK listed company last month including rights to the drug in China. I assume Chi-Meds deal to sell the drug in China on behalf of AZ transfers contractually to Luye, in other words, we still have the deal in place. Seroquel sales by Chi-Med in China were $35m in FY17 | nerdofsteel | |
28/6/2018 02:14 | Thank NofS! All looks good. We just await some of that key news now and then we may move higher again. Posting the link in 1520 again so it is live: | lauders | |
27/6/2018 11:42 | Excellent note from Edison published today on ASCO2018 including coverage on Fruquintinib | nerdofsteel | |
27/6/2018 10:36 | more coverage hxxps://jamanetwork. | nerdofsteel | |
27/6/2018 10:35 | on the subject of Stocktwits, there are currently 283 followers of HCM which has grown from <200 a year ago and <100 2 years ago. More would be welcome! | nerdofsteel | |
27/6/2018 09:25 | GW Pharmaceuticals in the news on the Nasdaq yesterday. The company is based in Cambridge UK. Announcement that the US FDA has approved Epidiolex for treatment of epilepsy. Some similarities with HCM. High volume of shares traded. But the share price did not budge at all($144) having reached a peak of $162 a month ago. The reason imho: hype-overload. | thornyone | |
26/6/2018 21:33 | Cisk, Thank you. | kinkell | |
26/6/2018 17:27 | try stocktwits, seeking alpha | cisk | |
26/6/2018 15:56 | Does anyone know a US bb which features HCM, please? | kinkell | |
22/6/2018 08:19 | If Savolitinib gets Breakthrough Therapy Designation from the FDA for NSCLC we can espect peak sales of $2.5bn for that indication alone, with Chi-Med getting royalties of 14-18% | nerdofsteel | |
21/6/2018 16:58 | Like this part, among others, from that link NofS: The interesting thing is what happens now. When drug trial results are exceptionally good the pharmaceutical company can apply to the regulators for it to be treated as a breakthrough therapy. If granted, this allows the business to fast-track the route to market, the idea being that since there is a medical need which has not been met, it should be made available to existing patients as soon as possible. This, however, is simply an added bonus. If that special status is not granted, the drug still comes to market — it just takes a bit longer. | lauders | |
21/6/2018 11:06 | For anyone who has not read it and is interested, this a great article on HCM from late last year. Anthony Hilton has called it correctly right from the 200p per share days..... | nerdofsteel | |
21/6/2018 10:53 | haha stranger things have happened, but I will settle for an mcap of $24bn by 2026 which is 6x what it is today. My forecast is based on a number of metrics. Is that ambitious? No, it's actually fairly conservative if the late stage pipeline success continues and all P3 trials are successful. There may be the odd hiccup along the way but I think we will get there. | nerdofsteel | |
21/6/2018 08:40 | Had a weird dream last night that HCM became the most valuable drug company in the world! I wonder if it could ever happen... | cisk | |
20/6/2018 16:11 | SP up 3.46% at the moment in US market | nimrod22 | |
20/6/2018 15:08 | yes! surely, must be. I assume they will not consider Fruquintinib or Savolitinib to be Chinese as they are headed by AZ and Lilly but we will have Sulfatinib in the next couple of years and that is wholly owned. Lots of news due, especially the big one, our first NDA. | nerdofsteel | |
20/6/2018 12:20 | Thank you NofS. Some interesting points in that piece: As China battles surging rates of cancer, heart disease and diabetes, sales of medicines are expected to hit as much as $175 billion by 2022, according to researcher Iqvia Holdings Inc. China is the world’s second-largest pharmaceutical market after the U.S. This also: Their plans are getting a boost from the government’s move in 2015 to overhaul regulations that had for decades slowed drug approvals and stifled innovation. These days innovative new drugs can reach the Chinese market in a fraction of the time the process once took. The risks: Yet the risks remain plentiful. Most Chinese companies are still awaiting approvals for their medicines, and the country still doesn’t have major novel drugs of its own. Also, a lot of biotech innovation in China still doesn’t include groundbreaking new mechanisms of treatment, or so-called first-in-class therapies. The future: Meanwhile, though, more money is likely to flow into China’s biotech sector. The Hong Kong Stock Exchange is starting to allow unprofitable biotech companies to list. Debra Yu, head of U.S. cross-border health-care investment banking for China Renaissance, predicts that will bring new investors, including some from the U.S., into the industry. “I believe in five to 10 years, several global blockbusters that benefit people around the world will come from China,” said Wu Xiaobin, BeiGene’s China head and former country manager at Pfizer China. “I don’t know which companies, but they will be Chinese.” Hmm.... HCM among them? | lauders | |
20/6/2018 08:37 | Nice article from Bloomberg yesterday on the rise of China's fledgling Biotech industry | nerdofsteel | |
19/6/2018 12:35 | Lower highs on the chart not good..also a massive head and shoulders pattern pointing down to approx £30-32 per share... | montynj | |
19/6/2018 08:03 | Then collapsed 8% overnight, what an up and down ride it is at the moment, pending news. | mad foetus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions